| pubmed-article:17621181 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17621181 | lifeskim:mentions | umls-concept:C2926606 | lld:lifeskim |
| pubmed-article:17621181 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17621181 | lifeskim:mentions | umls-concept:C2607943 | lld:lifeskim |
| pubmed-article:17621181 | lifeskim:mentions | umls-concept:C0271084 | lld:lifeskim |
| pubmed-article:17621181 | lifeskim:mentions | umls-concept:C0920367 | lld:lifeskim |
| pubmed-article:17621181 | lifeskim:mentions | umls-concept:C1531015 | lld:lifeskim |
| pubmed-article:17621181 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17621181 | pubmed:dateCreated | 2007-7-10 | lld:pubmed |
| pubmed-article:17621181 | pubmed:abstractText | To evaluate macular thickness measured by optical coherence tomography (OCT) during pegaptanib therapy for neovascular age-related macular degeneration (AMD). | lld:pubmed |
| pubmed-article:17621181 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17621181 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621181 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17621181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621181 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17621181 | pubmed:issn | 0275-004X | lld:pubmed |
| pubmed-article:17621181 | pubmed:author | pubmed-author:WilsonDavid... | lld:pubmed |
| pubmed-article:17621181 | pubmed:author | pubmed-author:StoutJ... | lld:pubmed |
| pubmed-article:17621181 | pubmed:author | pubmed-author:KleinMichael... | lld:pubmed |
| pubmed-article:17621181 | pubmed:author | pubmed-author:NolteSusanS | lld:pubmed |
| pubmed-article:17621181 | pubmed:author | pubmed-author:EmersonGeoffr... | lld:pubmed |
| pubmed-article:17621181 | pubmed:author | pubmed-author:FlaxelChristi... | lld:pubmed |
| pubmed-article:17621181 | pubmed:author | pubmed-author:LauerAndreas... | lld:pubmed |
| pubmed-article:17621181 | pubmed:author | pubmed-author:EmersonM... | lld:pubmed |
| pubmed-article:17621181 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17621181 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:17621181 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17621181 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17621181 | pubmed:pagination | 724-9 | lld:pubmed |
| pubmed-article:17621181 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:meshHeading | pubmed-meshheading:17621181... | lld:pubmed |
| pubmed-article:17621181 | pubmed:articleTitle | Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration. | lld:pubmed |
| pubmed-article:17621181 | pubmed:affiliation | Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA. | lld:pubmed |
| pubmed-article:17621181 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17621181 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
